LEADER 02446nam 2200385 450 001 9910262254503321 005 20230219122538.0 035 $a(CKB)4100000002580446 035 $a(NjHacI)994100000002580446 035 $a(EXLCZ)994100000002580446 100 $a20230219d2017 uy 0 101 0 $ager 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 14$aDie rechtliche Zula?ssigkeit von Placebokontrollgruppen in Arzneimittelstudien $eUnter besonderer Beru?cksichtigung der Blankoeinwilligung und der Zula?ssigkeit weiterer Kontrollvarianten /$fFranziska B. Friske 210 1$aGo?ttingen, Germany :$cUniversita?tsverlag Go?ttingen,$d2017. 215 $a1 online resource (xxv, 358 pages) 311 $a3-86395-321-5 330 $aClinical trials of medicinal products on human subjects are a balancing act between the protection of the study participant and the preservation of his dignity on the one hand and the constant striving for medical progress on the other hand. This applies likewise to the control group as an essential part of every clinical testing of pharmaceuticals without which no drug will receive marketing authorisation in Germany by the competent authorities. Nevertheless, significant gaps in the German legislation concerning this matter still remain as the German legislator has yet to implement any specific rules with regard to the handling and management of the control group in clinical trials. In view of this unsettled legal situation, the author critically analyses the core of the problem areas in this field's current research practice and creates solutions reflecting the interests of the study participant as well as the practical needs of medical research. Only legal clarity regarding the control group can provide for the safety that is crucial in this field of tension between ethics, medicine and the law. 606 $aPlacebos (Medicine) 606 $aClinical trials$xLaw and legislation 606 $aLaw$zGermany 615 0$aPlacebos (Medicine) 615 0$aClinical trials$xLaw and legislation. 615 0$aLaw 676 $a340 700 $aFranziska B$b Friske$01279753 801 0$bNjHacI 801 1$bNjHacl 906 $aBOOK 912 $a9910262254503321 996 $aDie rechtliche Zula?ssigkeit von Placebokontrollgruppen in Arzneimittelstudien$93015946 997 $aUNINA